AbbVie Inc. (ABBV) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in North Chicago, IL, United States. The current CEO is Scott T. Reents.
ABBV has IPO date of 2013-01-02, 55,000 full-time employees, listed on the NYSE, a market capitalization of $372.01B.
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a diverse portfolio of medicines across multiple therapeutic areas. The company's key products include HUMIRA for autoimmune diseases, SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis, IMBRUVICA and VENCLEXTA for blood cancers, and MAVYRET for hepatitis C, along with established brands such as Synthroid for hypothyroidism, Botox, Lupron, and Linzess for gastrointestinal conditions. AbbVie also offers specialized treatments in ophthalmology, neurology, and women's health, including eye care solutions and migraine therapies. Headquartered in North Chicago, Illinois, and incorporated in 2012, the company maintains research collaborations to advance its drug pipeline and expand its global reach.
